Indoco Remedies Ltd share price was up by 0.86% from the previous closing price of ₹321.25. Who are peers of Indoco Remedies Ltd? The peers of Indoco Remedies Ltd are Sun Pharmaceuticals ...

Aceclofenac is a nonsteroidal anti-inflammatory drug (NSAID), prescribed for fever and to relieve pain and swelling in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Albendazole ...

The Indian Pharmaceuticals industry plays a prominent role in the growth of the global pharmaceuticals industry. Indias pharmaceutical market, currently valued at $ 50 billion is the worlds third ...

Indoco Remedies Limited (Indoco), a fully integrated, research based pharma company with a strong global presence, announced of a strategic collaboration between Indoco Remedies and Clarity Pharma, UK ...

Indoco Remedies Ltd, a manufacturer and distributor of pharmaceutical products and services, today said it has acquired a 100 per cent stake in City-based pharma company La Nova Chem (India ...

In a setback for Indoco Remedies, the pharma company informed that it has received a warning letter from the USFDA for its facility in Goa's Verna region on December 17, sending the shares sharply ...

Shares of Indoco Remedies rose 1.85 per cent to ₹346.90 on the BSE at 2.38 pm on Tuesday. The company has received official action indicated (OAI) status from the US Food and Drug Administration ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...